ALK

Celebrating the past and future of allergy solutions for life

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy

Watch the video

News

See all

Post date
03/23/2023

Annual General Meeting in ALK-Abelló A/S held on 23 March 2023

Read more
Post date
03/02/2023

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
02/27/2023

Annual General Meeting in ALK on 23 March 2023

Read more
Post date
02/10/2023

ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)

Read more
Post date
02/08/2023

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
02/03/2023

Regulatory filing for house dust mite allergy tablet accepted for review in China

Read more
Post date
02/03/2023

Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022

Read more
Post date
01/27/2023

Release date of annual report 2022 for ALK and audio cast

Read more
Post date
12/21/2022

Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK

Read more

Strategy update: Focus areas during 2021-23

Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

ALK in brief

Allergy at a glance

Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.

Our solutions

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.